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Abstract: The traditional Mediterranean diet (MD) is associated with long life and lower prevalence
of cardiovascular disease and cancers. The main components of this diet include high intake of fruit,
vegetables, red wine, extra virgin olive oil (EVOO) and fish, low intake of dairy and red meat. Olive
oil has gained support as a key effector of health benefits and there is evidence that this relates to the
polyphenol content. Olive leaf extract (OLE) contains a higher quantity and variety of polyphenols
than those found in EVOO. There are also important structural differences between polyphenols
from olive leaf and those from olive fruit that may improve the capacity of OLE to enhance health
outcomes. Olive polyphenols have been claimed to play an important protective role in cancer and
other inflammation-related diseases. Both inflammatory and cancer cell models have shown that
olive leaf polyphenols are anti-inflammatory and protect against DNA damage initiated by free
radicals. The various bioactive properties of olive leaf polyphenols are a plausible explanation for
the inhibition of progression and development of cancers. The pathways and signaling cascades
manipulated include the NF-κB inflammatory response and the oxidative stress response, but the
effects of these bioactive components may also result from their action as a phytoestrogen. Due to the
similar structure of the olive polyphenols to oestrogens, these have been hypothesized to interact with
oestrogen receptors, thereby reducing the prevalence and progression of hormone related cancers.
Evidence for the protective effect of olive polyphenols for cancer in humans remains anecdotal and
clinical trials are required to substantiate these claims idea. This review aims to amalgamate the
current literature regarding bioavailability and mechanisms involved in the potential anti-cancer
action of olive leaf polyphenols.
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1. Introduction
Cancer is a group of diseases involving proliferation of mutated cells [1]. In 2012, over 14 million
new cases of cancer were reported [2], triggering a push to further develop treatments and preventative
strategies. Cancer is predominantly an age-related disease, therefore with better conditions of life and
increased longevity it is likely to continue increasing in prevalence. However, there are clearly factors
other than age that contribute to its development. The traditional Mediterranean diet (MD) has gained
robust scientific support for providing protection against some cancers [3,4]. The MD has shown an
ability to influence the inflammatory response, which plays a pivotal role in aging and in reducing its
age-associated non-communicable diseases such as cancer. However, the mechanisms of action behind
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the effects of the MD on inflammation are not entirely clear [5–7]. It has been suggested that the NF-κB
inflammatory response, eicosanoid pathways and oxidative stress via free radical formation, have
been suggested to play a role in MD related health benefits [5,8,9]. The diet, as a whole, has shown a
protective role in cancer, however, the distribution of people still consuming it is gradually receding
due to the spread of the western-type urban society, globalization and consumption [10]. Because
of this, it is important to understand whether any beneficial effects ascribed to the MD are due to a
particular component of the diet, rather than the whole diet. As one example, polyphenol bioactive
components have shown particular promise and have therefore been a research focus.
Extra virgin olive oil (EVOO) is typically used as a traditional component of the MD and has
also been correlated with improved cardiovascular disease and cancer outcomes [11,12]. EVOO is
manufactured by pressing olives to create a paste, which is churned to amalgamate oil droplets which
are then extracted. There is a considerable variation in EVOO characteristics that can be attributed
to the olive variety, the geographical location the olives were derived from [13] and the method of
oil extraction [14]. Intake of both MD and EVOO has been shown to correlate with a reduced overall
risk of cancer and is more specifically associated with reduced risk of cancers of the digestive system,
prostate and breast [12].
EVOO is primarily a monounsaturated fatty acid (MUFA) in the form of oleic acid, with minor
components including various phenolics [15]. It has been recognised that the polyphenol content plays
an important role in health benefits. The European Food Safety Authority (EFSA) have approved
the use of the general claim “olive oil polyphenols contribute to the protection of blood lipids from
oxidative stress” when oil contains no less than 5 mg of hydroxytyrosol (HT) and its derivatives
(such as tyrosol and oleuropein) per 20 mL OO [16] (Figure 1). There are several studies that have
shown that EVOO with higher phenolic content provides stronger anti-inflammatory and antioxidant
effects than OO with a lower phenolic content [17,18]. This suggests the phenolic component, rather
than the fat in the oil, is the effector.
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Figure 1. The olive polyphenol hydroxytyrosol and its derivatives, oleuropein and tyrosol (adapted 
from [19]). 
Olive tree leaves (Olea europaea) are widely used in traditional medicine in the Mediterranean 
region [20]. In the Bible, the olive plant is referenced numerous times for its medicinal use [21]. The 
bioactive  properties  of  the  leaf  have  created  a  foundation  for  use  as  an  antioxidant,  anti‐
hypertensive,  anti‐atherogenic,  anti‐inflammatory,  hypoglycemic,  and  hypocholesterolemic 
treatment  [20]. Olive  tree  leaves contain similar polyphenols  to  those  found  in EVOO or  the  fruit 
Figure 1. The olive polyphenol hydroxytyrosol and its derivatives, oleuropein and tyrosol (adapted
from [19]).
Olive tree leaves (Olea europaea) are widely used in traditional medicine in the Mediterranean
region [20]. In the Bible, the olive plant is referenced numerous times for its medicinal
use [21]. The bioactive properties of the leaf have created a foundation for use as an antioxidant,
anti-hypertensive, anti-atherogenic, anti-inflammatory, hypoglycemic, and hypocholesterolemic
treatment [20]. Olive tree leaves contain similar polyphenols to those found in EVOO or the fruit itself,
albeit at a much higher concentration [20,22]. Consequently, olive leaf extract (OLE) may hold an even
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greater potential than EVOO for improving health outcomes. During EVOO processing leaves can
unintentionally be left in the mixture if the separation methods are inadequate, alternately leaves can
also be added to EVOO mixtures to provide health benefits and improve flavor [23]. The addition
of leaves increase the phenolic and chlorophyll content of the oil but also the organoleptic traits as
measured in volunteer taste tests [24]. Components of OLE that are not detected in the oil from the
fruit include several flavonoids, namely luteolin and apigenin, which have demonstrated anti-cancer
properties [25–29]. In addition, the structure of phenolics differs between the olive fruit and leaf, with
OLE containing a higher proportion with a glycoside moiety (Figure 2 and Table 1) [19]. The presence
of a glucose molecule could play an important role in respect to both bioavailability and bioactive
potential of the polyphenols, thereby impacting the health benefits for humans.
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Figure 2. Most abundant phenolics present in OLE. Structures (a) and (b) are flavonoids. Structures 
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is adapted from [19]. 
Table 1. Comparison of phenolic compounds found  in olive  leaf extract and olive oil, with values 
reported in mg/kg [30]. Luteolin, apigenin, verbascoside and oleuropein all have a glucoside moiety. 
Values are an estimated range generated from a comprehensive review of the published literature.  
  Hydroxytyrosol  Oleuropein  Luteolin‐7‐
Glucoside 
Apigenin‐7‐
Glucoside  Verbascoside 
Oleuropein 
Aglycone  Reference 
Olive oil  
mg/Kg 
131.77 ± 32  ND  ND  ND  ND  17.24 ± 1.15  [30] 
3.0 ± 0.2  ND  ND  ND  0.08 ± 0.02  NM  [31] 
12.5  ND  NM  NM  NM  NM  [32] 
4.3–9.9  ND  4.0–7.6  1.5–2.6  ND  67.7–136.4  [33] 
0.15–1.53  ND  ND  ND  ND  0.35–6.43  [34] 
Olive leaf  
mg/Kg 
NM  26,471.4 ± 1760.2  4208.9 ± 97.8  2333.1 ± 74.7  966.1 ± 18.1  NM  [35] 
ND  19,050 ± 880  155 ± 10  207 ± 10  1428 ± 46  NM  [31] 
NM  19,860 ± 54  NM  NM  200 ± 40  NM  [36] 
NM  22,610 ± 632  970 ± 43  1072 ± 38  488 ± 21  NM  [37] 
NM  5173–12,921  219–444  192–488  213–501  NM  [38] 
Abbreviations: not detected: ND; not measured: NM. 
Although  there  is a  large body of research  that has  investigated  the phenolic components of 
olive  products  and  the  benefits  they  provide  to  human  health  [39–42],  there  are  currently  no 
Figure 2. Most abundant phenolics present in OLE. Structures (a) and (b) are flavonoids. Structures
(d) and (e) are esters of (c) which is a simple phenolic. The glucoside moieties are circled. This figure is
adapted from [19].
Table 1. Comparison of phenolic compounds found in olive leaf extract and olive oil, with values
reported in mg/kg [30]. Luteolin, apigenin, verbascoside and oleuropein all have a glucoside moiety.
Values are an estimated range generated from a comprehensive review of the published literature.
Hydrox tyr sol Oleuropein Luteolin-7-Glucoside
Apige in-7-
Glucoside Verbascoside
Oleuropein
Aglycone Reference
Olive oil
mg/Kg
131.77 ± 32 ND ND ND ND 17.24 ± 1.15 [30]
3.0 ± 0.2 ND ND ND 0.08 ± 0.02 NM [31]
12.5 ND NM NM NM NM [32]
4.3–9.9 ND 4.0–7.6 1.5–2.6 ND 67.7–136.4 [33]
0.15–1.53 ND ND ND ND 0.35–6.43 [34]
Olive
leaf
mg/Kg
NM 26,471.4 ± 1760.2 4208.9 ± 97.8 2333.1 ± 74.7 966.1 ± 18.1 NM [35]
ND 19,050 ± 880 155 ± 10 207 ± 10 1428 ± 46 NM [31]
NM 19,860 ± 54 NM NM 200 ± 40 NM [36]
NM 22,610 ± 632 970 ± 43 1072 ± 38 488 21 NM [37]
NM 5173–12,921 219–444 192–488 213–501 NM [38]
Abbreviations: not detected: ND; not measured: NM.
Although there is a large body of research that has investigated the phenolic components of olive
products and the benefits they provide to human health [39–42], there are currently no approved
claims in regard to OLE. OLE not only contains a higher quantity and variety of polyphenols than
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those found in EVOO, but many of the polyphenols also contain a glucose moiety. This structural
difference in the polyphenols may have important consequences by altering their capacity to improve
health outcomes [43,44]. In previous work, OLE polyphenols have demonstrated the ability to inhibit
proliferation of several cancer cell lines including pancreatic [45], leukaemia [46] and breast [28,47].
Cellular models for breast and prostate cancers have been inhibited by the olive polyphenols oleuropein
and HT [48–51]. Importantly, oleuropein and HT have consistently been reported to discriminate
between cancer and normal cells; inhibiting proliferation and inducing apoptosis only in cancer cells.
The intake of polyphenols in observational studies is difficult to quantify and therefore assign effect
and intervention studies in regards to cancer have not been carried out, therefore the relationship
between polyphenols and cancer outcomes in humans has not been substantiated.
Research into the anti-cancer properties of olive polyphenols is abundant with a focus on the
health effects of EVOO. Evidence suggests that the bioactive components of OLE, although similar to
EVOO, may be more potent and therefore show more potential for improving health outcomes. This
review aims to amalgamate the current literature regarding bioavailability and anti-cancer mechanisms
involved in OLE polyphenol action. The literature identified for this review was found using the
search engines PubMed-NCBI, Scopus and ScienceDirect with a combination of block searching and
pearl-growing. Key words used for the search were olive leaf extract, polyphenols, cancer, oleuropein,
hydroxytyrosol, Mediterranean diet, inflammation, and bioavailability. The key components from the
research articles pivotal to this review have been summarized in Supplementary Table S1.
2. Olive Leaf Polyphenols
The Mediterranean region, where olive trees are predominantly grown, is characterized by
extended periods of sunlight and high rates of pathogen and insect attack. To combat these stressors,
olive trees synthesize high volumes of polyphenols which are largely stored in their thick leaves [52].
The concentration and variety of polyphenols present in the leaves will be influenced by many factors
such as geographical location, cultivar of tree, and the age of the tree [49]. Polyphenols comprise
multiple phenolic groups, each consisting of an aromatic ring with a varying number of hydroxyl
groups [19]. The polyphenols predominantly occur in a conjugated form, with one or several sugars
attached to the hydroxyl group [53]. The number and structure of phenol rings in a polyphenol are
used for classification and will determine its bioactive properties. The main phenolic compounds
are the secoiridoids (namely oleuropein) and flavonoids (Figure 2), these have shown the ability to
influence human and animal inflammatory and metabolic biomarkers [41,54–56].
Secoiridoids are a group of compounds found exclusively in plants of the Olearaceae family, and
make up the majority of olive polyphenols (~85% of olive leaf polyphenols) [57]. In OLE the secoiridoid,
oleuropein is the most abundant polyphenol (Figure 2), while its derivatives oleuropein aglycone,
oleoside, and ligstroside aglycone are also present at varying concentrations [19]. The research
surrounding oleuropein is abundant. It has been associated with numerous health benefits including
the ability to: lower blood pressure in rats [58], decrease plasma glucose concentrations in rats [55],
inhibit the growth of microbes grown on agar plates [59], inhibit cultured parasitic protozoans [60] and
has also shown the ability to induce apoptosis in cancer cell models: colorectal [61], breast ([61–63]
and prostate [48]. Human trials looking into the effect of OLE on cancer do not yet exist.
Hydrolysis of oleuropein gives rise to oleuropein aglycone, elenolic acid, HT and a glucose
molecule (Figure 3) [64]. HT is a phenolic alcohol and the second most abundant phenolic acid
in olive leaf. Tyrosol is another phenolic acid derived from oleuropein, but is found in low
concentrations in the leaf (Table 1). Other related compounds include verbascoside, which also
has demonstrated anti-inflammatory, anti-oxidant and antineoplastic properties similar to the other
olive leaf bioactives [65], as well as caffeic acid (220.5 ± 23.3 mg/kg) [35] and p-coumaric acid.
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OLE consists of a number of flavonoids (~2% of olive leaf polyphenols) including luteolin,
apigenin (Table 1), rutin (495.9 ± 12.2 mg/kg) [35], catechin (19.3–32.6 mg/g dried extract) [66] and
diosmetin (8.70 mg/g dried extract) [22]. Luteolin is able to suppress inflammatory expression in
macrophages and adipocytes [67]. Apigenin is present at relatively low concentrations within live
leaf, but it ha lso been linked to anti- nflammatory, anti-cancer and anti-oxidising properties [68].
Other components of OLE that occur in smaller concentr tions i clude oleanolic acid [69], vanillin
and vanillic acid, [59], as well as tocopherols and β ca ote e [70]. In human studi s, α tocopherols
h ve been correlated to lower pro tat cancer mortality, but β carotene at high concentrations, has
been cor e ated to incr ased mor ality of lung cancer patients [71].
Thousands of phytochemicals with differing attributes have been iden fied and isolated, but a
point which is often overlooked i that it can be combination of compounds that induc heal h
benefits [72–74]. Within plants, polyphenols are present in mixtures and not s independent
compounds; the polypheno s have evolv d together, generally for he purpose f deterring i s ct
feeding and the levels of the different bioactives with these mixtures need t be considered wh n
looki at bioactive properti s for human health. While evolutionary purp se for the polyphenol
mixtures it not for human ben fit, the nature of the mixtur s may nevertheless be important for
human health. Sev ral studies have demo strated th t th phenolic compounds from OLE may
dis lay a synergistic eff ct when in the same proportions as occurring naturally in the olive leaf. The
secoiridoids, flavonoids and other phenols i OLE provide a str nger anti-microbial and antioxidant
effect when working together, s pposed to the phenolics independently [59,75,76]. Through the use
of ifferent antioxidant assays it was determined that OLE flavonoids, simple phenols and secoiridoids
utilize differ nt mechanisms o exert an anti-oxidant effect [75], which at least in p rt explain their
additive effect.
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3. Bioavailability of Olive Leaf Polyphenols
In nutrition, bioavailability refers to the amount of compound/nutrient extracted from a food or
supplement that is capable of being absorbed and made available for physiological use by the body [77].
There are many factors that will influence the bioavailability of a compound including the vector, time
taken for absorption, structure of compound/bioactive target or the individual person [78]. The matrix
that the olive leaf is consumed and maintained may also have an impact on the bioavailability of
the active components. The leaves can be consumed in tea, as a powder or in an extract form As an
example, De Bock and co-authors demonstrated that the polyphenol derivatives measured in plasma
differed when the OLE was administered as a safflower oil compared to a glycerol matrix [79].
The ability to produce health benefits in different organs throughout the body requires that the
bioactive olive leaf polyphenols, or their metabolites, are able to infiltrate these areas. After an acute
load of olive phenolic (3 g phenolic extract from olive cake/kg of body weight) extract in mice, samples
demonstrated that phenolic derivatives and conjugates (oleuropein, tyrosol, HT and luteolin) were
absorbed, metabolised and present in the plasma (oleuropein derivative: max 4 h: 24 nmol/L and HT:
max 2 h: 5.2 nmol/L), the heart (luteolin derivative at 1 h: 0.47 nmol/g), kidney (luteolin derivative 1
h: 0.04 nmol/g, HT max 4 h: 3.8 nmol/g), testicles (olueropein derivative Cmax 2 h: 0.07 nmol/g and
HT max 2 h: 2.7 nmol/g) and had even passed the blood brain barrier (olueropein derivative at 2 h:
2.8 nmol/g) [80].
The research looking into bioavailability of polyphenols from OLE in commercial glycerol
formulations consistently show that oleuropein is bioavailable in humans but there is differing evidence
regarding the metabolites found in plasma [79,81]. De Bock reported the primary metabolite recovered
to be glucoronidated and sulphated HT [79]. In contrast, Kendall’s group reported that no HT was
detected in urine samples, but glucuronic acid conjugates, derived from oleuropein aglycone were
detected [81]. In rats fed oleuropein, liquid chromatography-mass spectrometry (LC-MS) detected
oleuropein, oleuropein aglycone, elenolic acid and HT both within faeces and urine at 24 h [82]. This
demonstrates the stability of these compounds and therefore the potential ability to reach other parts
of the body intact and in an active form.
Corona et al. (2006) reported HT and tyrosol traversed the perfused small intestine membrane of
rats but oleuropein did not, and would therefore likely reach the large intestine intact [83]. Incubating
with anaerobic human microbiota with olueropein resulted in rapid and extensive microbiota
degradation of oleuropein to HT and other metabolites [83]. Specifically the gastrointestinal bacterium
Lactobacillus planatarum has the ability to metabolize oleuropein to HT [84]. The microbiota acting
to break down oleuropein to HT would have an important impact on bioavailability if oleuropein
cannot traverse membranes, but HT and other metabolites can, as reported by Corona et al. 2006.
Another study has since found that oleuropein orally administered to rats resulted in the production of
oleuropein metabolites from the gastrointestinal tract as well as metabolites in the blood [82]. The most
recent research looking into the metabolism of oleuropein verses oleuropein aglycone in rodents (5 mg
phenol/kg/day) found that oleuropein resulted in the greatest bioavailabilty (measured by the highest
content of HT excreted in urine) and a greater diversity of microbial metabolites due to its superior
ability to reach the colon intact [44].
Glycosylation of Polyphenols
The glucose moiety that is present on many of the olive leaf polyphenols could have an important
impact on their bioactive properties. The glucose molecule significantly increases the molar mass of
the polyphenol; oleuropein is 540.51 g/mol, where the oleuropein aglycone is 394 g/mol. The glucose
molecule may improve stability and bioavailability, and facilitate cell entry but it also may impede
bioactive properties.
Through collection and processing methods of olives and leaves, different glycosylation enzymes
are activated [85]. The transformation of oleuropein is dependent on the type of glycosylation enzyme
acting (β-glucosidase, hemicellulase, tannase, neutral protease, cellulase, glucoamylase, papain,
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alkaline protease, amylase, β-glucanase) and this will result in varied concentrations and ratios
of HT, oleuropein aglycone, elonolic acid and total phenolics [86,87]. The combination of polyphenols
may improve the OLE biostability, insuring polyphenols are still present in the olive leaf extract when
consumed by humans but also improving the polyphenols ability to reach different areas of the body
intact. For example oxidoreductase enzymes reduce the abundance of oleuropein in OLE, but the
presence of HT is able to inhibit their action [86].
Olive leaf polyphenols containing a glucose moiety have been suggested to play an important
role in relation to cancer cell treatment. A study looking at oleuropein found removal of the glucose
moiety reduced its ability to inhibit proliferation of cancer cells [43]. This indicated that the hydrophilic
glucose may be enabling oleuropein to enter cells via GLUT transporters to create the anti-cancer affect.
GLUT mRNA expression is often increased in cancer cells and is correlated to cancer progression [88].
The glucose moiety in oleuropein may facilitate its diffusion into these cells in precedence to normal
cells and therefore result in a greater inhibitory effect on cancer versus normal cells. Another study
has indicated that the olive flavonoid apigenin is able to reduce the expression of GLUT1 in prostate
cancer cell lines thereby inhibiting proliferation of the cancer [29].
Another study looking at the effect of oleuropein (dissolved in water) verses oleuropein aglycone
(dissolved in ethanol 100%) (6 to 100 µM) in MCF-7 found the aglycone to be more effective at reducing
cell viability [89]. This would suggest that the glycoside is essential for anti-cancer effects.
Protective effects of the MD and EVOO against cancers, as discussed in the introduction, are
primarily associated with cancers of the digestive system. This could be due to the bioavailability
of the polyphenols, with the polyphenol constituents creating the anti-cancer effects not being able
to reach other parts of the body to have an impact. Consequently if the glucose moiety, a prominent
characteristic of olive leaf polyphenols improves bioavailability it may also improve protective effects
for different cancers.
4. OLE and Evidence of the Ability of Olive Leaf Polyphenols to Scavenge Nitric Oxide and
Quench Reactive Oxygen Species
Reactive oxygen species (ROS) and nitrogen species (NOS) are essential for cell function. They are
involved in energy supply, detoxification, chemical signaling and immune response. However, when
overproduced they can create stress by damaging DNA, lipids and proteins and they are widely
accepted to play an important role in pathologies and aging [20,90]. Chronic disease is associated with
oxidative stress, therefore an increased antioxidant intake or intake of compounds that enhance the
body’s own antioxidant system is expected to reduce the risk of these diseases. It was this hypothesis
that has led to an increased interest in antioxidants and their bioactive properties. Phenolics are one
group for which there is robust evidence supporting the health promoting effects of antioxidants.
There is a general consensus that olive leaf phenolics have a strong ability to scavenge nitric oxide
(NO) and quench ROS [91,92].
Antioxidant properties have been an important focus of research into polyphenols and are a
widely accepted mechanism for their health benefits. However, it has been suggested that several
constraints impede polyphenol in vivo scavenging of radicals, and that they would be inefficient at
mounting an antioxidant defense [93]. Concerns that have been highlighted include bioavailability
(the anti-oxidizing agent must reach these radicals in an active form to quench them) and kinetic
constraints for antioxidant scavenging (radicals may actually react with other biological molecules
such as DNA and lipids in the cell at the same rate as the antioxidants) [93]. This could mean
that a very high concentration of polyphenols would need to be ingested to perceive any effect
in humans. Instead it is suggested that antioxidant compounds, such as polyphenols, are able to
activate transcription factors such as nuclear factor (erythroid-derived 2)-like 2 (Nrf2) that bind to
the Electrophile Response Element (EpRE) and thereby transcribe genes for protective enzymes that
provide the health benefits (Forman et al., 2014 and Figure 4). Several in vitro studies using humans
cells and animal in vivo studies investigating olive polyphenols have supported Nrf2 activation and
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its consequential expression of protective genes [72,94]. Conversely, a recent human intervention
study has shown no evidence of altered phase II enzyme expression (the downstream product of Nrf2
activation) in peripheral blood mononuclear cells following consumption of HT (5 mg and 25 mg per
day in olive mill waste water) [95]. The olive mill waste water was tested to confirm oleuropein was
not present.
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The Xenohormesis hypothesis suggests the stress-induced secondary metabolite production
in plants is recognized by humans upon consumption, and these signals initiate stress response
pathways [72,73]. Similarities in the human and plant extracellular signal-regulated kinase (ERK)
pathways (these are able to activate many transcription factors and play an important role in cell
regulation functions) show that polyphenols are able to activate pathways, such as AMP-activated
protein kinase (AMPK) and hold the potential to modulate redox and mitochondrial signaling [96,97].
During eukaryotic evolution, glucose was the preferred carbon source. Rapid cell growth was the best
way to utilize glucose, and AMPK activation provided the off switch mechanism in this process [72].
Therefore, AMPK activation (or similar pathways) could result in decreased ATP and increases in
mitochondrial free radicals, implicating protection from chronic disease and aging [72]. Evidence for
this theory was provided by microarray analysis of gene expression after EVOO treatment of breast
cancer cells. These results demonstrated up-regulation of AMPK, and the top Canonical pathway
regulated was the Nrf2 Mediated Oxidative stress pathway [72].
HT in vitro studies using human cell lines has been shown to up-regulate the expression of
endogenous antioxidant genes (Heme Oxygenase 1 (HO-1), NAD(P)H-quinone oxidoreductase
(NQO1), Glutathione (GSH)) via Nrf2 overexpression. The c-Jun N-terminal kinase (JNK) pathway
plays an important role in inflammatory signaling. The JNK pathway was up-regulated following
treatment with HT and inhibiting this pathway established its requirement for GSH and p62 regulation.
However, HO-1 or NQ-1 were unaffected [94]. p62 inactivates Keap1, increasing Nrf2 in the nucleus
and consequently increasing the expression of oxidation defense enzyme genes [98]. Oleuropein in
a human in vitro model has also been shown to activate Nrf2 and HO-1 expression [99]. However,
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in vivo human trials with HT have failed to find an up-regulation of phase 2 enzymes which are the
by-product of EpRE and Nrf2 stimulation [95].
5. Olive Leaf Properties That Protect against Development and Progression of Cancer
Genetic changes are involved in the prevalence of cancers, however it is environmental
and lifestyle factors such as obesity [100], unbalanced diet, tobacco, lack of exercise and alcohol
consumption that account for the majority of the attributing cause [101]. Olive leaf contains strong
anti-oxidants, it would be logical to conclude that these would help in mitigating the effect of genetic
lesions that give rise to cancer. However, olive leaf has also attracted attention as a potential cancer
treatment [28,46,102,103]. In previous work, olive leaf polyphenols have demonstrated the ability
to inhibit the proliferation of several cancer cell lines including pancreatic [45], leukaemia [46],
breast [28,47,49], prostate [48] and colorectal [61]. Importantly, oleuropein and HT have consistently
been reported to discriminate between cancer and normal cells; inhibiting proliferation and inducing
apoptosis only in cancer cells [48,49]. The challenge with relating the anti-cancer effects in cell models
to in vivo arises when considering bioavailability of the polyphenols. This could explain why OO
protective effects in humans show a strong association with cancers of the digestive system [12].
In other cancers OO phenolics has been suggested to act as phytoestrogens and anti-inflammatory
agents, thus producing a protective effect.
A higher risk of breast cancer is linked to over-exposure to oestrogen [104,105] and growth of
breast cancer can be stimulated by estradiol, which binds to the oestrogen receptor (ER). This receptor
is an important biomarker and target for breast cancer prevention and treatment [106]. Work with
breast cancer cell lines and OLE polyphenols have indicated potential mechanisms of action that
include action as a phytoestrogen. Oleuropein and HT both possess an aromatic ring that is similar to
that in estradiol, therefore these compounds are hypothesized to compete with oestrogens for receptor
binding sites [50,107]. In the MCF-7 breast cancer cell line, HT and oleuropein (at doses between 10 and
75 µM) dose-dependently prevented cell proliferation through inhibition of the oestrogen activated
ERK1/2 signaling pathway but did not show a direct effect on the mediation of ER gene expression [50].
It was later shown that oestrogen responses were also mediated by the GPER/GPER30 receptors, of
which HT and oleuropein are agonists [108]. Despite both oestrogen and the polyphenols showing the
same mechanism of receptor binding, they have opposite effects. Oestrogen leads to cell proliferation,
while polyphenols lead to apoptosis or cell death. Both activate the ERK1/2 pathways but it has been
proposed that the length of activation could influence the effect, with prolonged activation leading to
apoptosis, and short-term to cell proliferation [108]. Sustained ERK activation has previously been
demonstrated to result in inhibition of MCF-7 cell growth [109]. In vivo studies looking at olive leaf
polyphenols also appear to support an anti-cancer effect. Oleuropein (125 mg/kg of diet) slowed
tumor growth and inhibited cancer metastasis after MCF-7 cell xenograft establishment in mice [110].
OLE dissolved in water (150 and 225 mg/kg/day) reduced tumour volume and weight in mice after
breast cancer xenograft [111].
The aromatase (CYP19) enzyme is the catalyst for the rate determining reaction in oestrogen
synthesis. Inhibiting CYP19 effectively prevents oestrogen synthesis and because high levels of
oestrogen are linked to breast cancer, this holds potential as a treatment [112]. A recent clinical
study has shown that amylase inhibitors taken daily for 5 years were successfully able to reduce
the incidence of breast cancer in high-risk postmenopausal women [113]. In MCF-7 cells, luteolin
suppressed CYP19 transcription potentially via activator protein-1 (AP1) and C/EBP binding to the
aromatase promoter [26].
The olive flavones apigenin and luteolin have been shown to act as aryl hydrocarbon receptor
(AhR) antagonists in mouse cell lines [114]. Upon ligand binding, AhR is translocated to the nucleus
where it activates response elements in the DNA sequence and consequent production of xenobiotic
enzymes [115]. Other work has found that AhR in cancer cell lines acts as a tumour suppressor through
diminished DNA replication and G0/G1 arrest [116]. Another study has reported that apigenin
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suppresses the growth of MCF-7 cells, inhibiting the NF-κB signaling pathway, the phosphorylation
of IkBα, and nuclear translocation of p65 within the nucleus [27]. Apigenin was not found to inhibit
cell survival signaling through mediators such as AKT, ERK, JNK, or p38, but it decreased STAT3
transcriptional activity in the cells, indicating that this compound induces growth-suppressive activity.
The transcription factor STAT3 is more specifically involved in inflammatory signaling within cancer
tumours and interacts with cytokines [117], thus by inhibiting STAT3, luteolin could also be having
an anti-inflammatory effect. In another study oleuropein was cytotoxic to MDA-MB-231 and MCF-7
cells, avoiding damage to normal cells, with apoptosis taking place via induction of the mitochondrial
pathway [49]. MCF-7 cell proliferation was inhibited by oleuropein at the S-phase of the cell cycle by
an up-regulation of the p21 gene, and inhibition of NF-κB and its target D1 gene expression.
In PC3 and DU145 prostate cancer cell lines, HT has demonstrated the ability to interfere with
cell proliferation [51]. HT also activated mitogen-activated protein kinase (MAPK), ERK, p38 MAPK
and JNK. However, when inhibited by specific antagonists, HT was still able to inhibit cell growth.
The authors concluded that HT was able to induce apoptosis in cancer cells via the generation of
superoxide dismutase (SOD) and extracellular ROS.
Work using the prostate cancer cell lines, LNCaP and DU145, found that oleuropein was
pro-oxidative, causing loss of viability, but in non-malignant cells (a benign hyperplastic prostatic
epithelial cell line) oleuropein acted as an anti-oxidant [48]. The downstream products of EpRE
activation were all increased with oleuropein; pAkt, y-glutamylcysteine (y-GCS), heme oxygenase-1
(HO-1) and ROS. Interference with pAkt was proposed as the mechanism enabling cell apoptosis in
these prostate cancer cell lines [48].
5.1. Anti-Inflammatory Properties of Olive Leaf Polyphenols and Their Effects on Cancer
Inflammation is the natural defense mechanism against foreign threats, and its mechanisms
are essential for survival. However, chronic inflammation, even at low levels, has been correlated
to many health complications and age-associated diseases, including but not limited to cancer and
cardiovascular disease [118]. The NF-κB signaling pathways play a pivotal role in inflammatory
response and are an attractive target for preventing inflammation. NF-κB resides inactive within the
cytoplasm due to the presence of IκB kinase, an inhibitor enzyme, therefore it can be activated very
quickly to initiate cytokine and prostanoid production. There is strong evidence that olive polyphenols
are able to interact with these pathways [119–121].
The cyclooxygenase 2 (COX-2) enzyme plays an important role in inflammation as the catalyst
for the synthesis for prostanoids and hence an inflammatory response [122]. Cellular studies with
OLE polyphenols have found a protective effect in relation to inflammation; a down-regulation of
NO and COX-2 [120,123–125]. Inhibition of the Toll-like receptor (TLR) signaling induced by LPS was
demonstrated not only by down-regulation of iNOS and COX2, but also by a decrease in ERK1/2,
JNK and nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (IκBα)
phosphorylation in vitro after oleuropein treatment [120] (Figure 5). In down-regulating this pathway
the pro-inflammatory enzymes interleukin 6 (IL-6) and interleukin 1β (IL-1β) and the gene AP-1
were also down-regulated. In human monocytes HT inhibited LPS induced COX-2 and prostanoid
production, however, it increased TNF-α. In contrast in human cell models tyrosol down-regulated
TNF-α and induced NF-κB, JNK and ERK phosphorylation and COX-2 expression [126] (Figure 5).
Lastly the olive flavonoid luteolin regulated IL-1β induced COX-2 expression via ERK, JNK and
NF-κB [127].
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Work looking at the effects of oleuropein in MCF-7 has shown that it is able to induce apoptosis via
up-regulating p53, and consequently the transcription of Bax/Bcl-2 apoptotic genes [62]. Other studies
have also measured a change in p53 and Bax expression with oleuropein inhibition of cervical cancer
cells [140] and p53 pathway up-regulation with oleuropein inhibition of colorectal cancer cells [61].
In vivo, luteolin (10 mg/kg/day) reduced both volume and weight of tumors in a prostate
xenograft mouse model and in vitro, using the prostate cancer cells PC-3, it down-regulated VEGF
phosphorylation of VEGF2 receptor and its downstream inflammatory markers IL-8 and IL-6 [25].
If VEGF is correlated to PGE2, as in the breast cancer models mentioned above, then it could be a
downstream effect of COX-2 inhibition.
PGE2 expression pushes the immune response from a T-helper 1 (Th1) (including cells
such as Natural killer (NK) cells) to a Th2 (such as mast cells) and Th17 mediated response,
which is less effective at fighting off infections or protecting from cancer [141]. This potentiates
acute, local inflammation driven by phagocytes, which is less aggressive than the Th1/Th17
response [141]. By down-regulating COX-2, the balance will shift back to Th1, which may improve
immune-competence. For example COX-2 knock out in breast cancer cells inhibited tumour growth by
enhancing T-cell survival and immune surveillance in tumours [142].
The tumour microenvironment has an important impact on tumour progression and metastasis,
therefore its manipulation has been suggested as a target for cancer therapy [143]. It has been
demonstrated in breast cancer MCF-7 cells that tumour associated macrophages are able to enhance
COX-2 levels in the tumour. Conversely inhibiting COX-2 in macrophages was able to inhibit levels in
the tumour [144]. In several human intervention studies with olive polyphenols, COX-2 expression
in immune cells was down-regulated [145,146]. In cancer patients this could potentially lead to a
down-regulation of COX-2 in tumours and thereby inhibit tumour progression. In other intervention
studies the inflammatory markers NF-κB, p65, IKKβ, and IKKα [147] and NF-κB, IL-6 and IL-1β [148]
have been down-regulated with olive polyphenols. These studies measured changes after single
40 mL doses of EVOO (containing the olive polyphenols), quantities achievable in an individual's
standard diet.
5.3. Quinone Hypothesis for Anti-Cancer Properties of Olive Leaf
As quinones, olive leaf polyphenols could bind to the cysteine residues of NF-κB in cancer
cells and manipulate gene expression. This would explain the observed gene expression in in vitro
models [46,120,126]. A recent study has indicated olive leaf polyphenols in a quinone form could
interact with Topoisomerase IIα [149]. The olive leaf polyphenols oleuropein, verbascoside, and HT
were categorized by Vann et al. as Topoisomerase IIα poisons. Topoisomerase IIα is an enzyme
essential for cell survival, catalysing the breaking and re-joining of the DNA helix to remove tangles
and playing an important role in cell replication. Acting as Topoisomerase IIα poisons the polyphenols
increased DNA cleavage, this effect was 10–100 times stronger in the presence of an oxidant [149].
This is consistent with the idea that the polyphenols have been transformed into quinone electrophiles,
which are then able to bind to cysteine residues. This study also demonstrated that the olive leaf
polyphenol tyrosol was unable to act as a poison consistent with its inability to form a quinone and
bind to the cysteine residue within Topoisomerase IIα.
Although potentially dangerous in normal cells, Topisomerase IIα is an important target for cancer
treatment. Due to the requirement of an oxidant environment, this might explain why no toxicity has
been shown in normal cells in comparison to tumour cell models; the quinones were not formed.
6. Conclusions
There is strong evidence from cell models which demonstrates that olive polyphenols, and
specifically the combination found in olive leaf, are able to modulate and interact with molecular
pathways and in doing so may inhibit the progression and development of cancer. However, it is
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important to acknowledge that cell models are very different from the complex human body and
applying these findings to cancer outcomes in humans is difficult.
Meta-analysis correlating the consumption of a MD and OO in humans to protection from
digestive system, prostate and breast cancers [4,12], suggest that the effects may be constrained by
bioavailability but also directs to a phytoestrogenic mechanism of action. Not only are the reduced risk
of oestrogen related cancers in females correlated to protective effects of phytoestrogens, but a recent
meta-analysis has correlated a lower risk of prostate cancer with phytoestrogen consumption [150].
The evidence suggests that olive polyphenols may act differently when in different combinations
and at different concentrations. The presence of a glucose molecule, one factor that differentiates olive
leaf polyphenols from OO polyphenols, is likely to affect the bioavailability and therefore bioactive
properties. Changes to microbiota and microbiota-mediated degradation of polyphenols, demonstrate
the glucose molecule has an effect.
Both cell models and human intervention studies demonstrate olive polyphenols are creating an
anti-inflammatory change involving NF-κB inhibition. The down-stream products of NF-κB: including
COX-2, IL-6, IL-8, IL-1β are expressed at lower levels creating a tumour micro-environment that no
longer facilitates progression or development of cancers. This may account for the lower prevalence of
cancer in people consuming a MD.
To answer the question “does OLE protect against cancer?” is difficult. Evidence is available in
cell and animal models to support the conclusion that OLE does have beneficial effects and there is
anecdotal evidence that olive polyphenols have a protective effect against cancer in humans. People
consuming the MD have a lower prevalence of cancer, the MD consists of a high content of polyphenols,
and olive leaf is an excellent source of many of these polyphenols. However, in order to prove that
OLE improves cancer outcomes in humans, clinical trials would be required.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/8/8/513/s1,
Table S1: Olive leaf polyphenol treatment in different cancer models; in vivo and in vitro.
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JNK c-Jun N-terminal kinase
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